ProPhase Labs, Inc. Income Taxes Receivable, Current
ProPhase Labs, Inc. (PRPH) had Income Taxes Receivable, Current of $502.00 thousand as of 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Notes › and Others
us-gaap:IncomeTaxesReceivable · last filed 2018-05-15
- 2018-03-31: Income Taxes Receivable, Current $502.00K.
- 2017-12-31: Income Taxes Receivable, Current $502.00K.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2018-03-31 | $502.00K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $502.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |